There is no established BPC-157 dose. The research that every dosing chart descends from was done in rats, and it tested doses a million-fold apart, from 10 picograms to 10 micrograms per kilogram of body weight [[2]][[3]]. It reported one healing result across that whole span, so it contains no dose-response curve to scale from. The popular 250 to 500 mcg figure does not appear in the literature; it divides the vial cleanly, since 5 mg makes 20 doses of 250 mcg and 10 mg makes 40. BPC-157 is not an approved medicine anywhere, it is sold labelled for research use only rather than for human consumption, and it is prohibited in sport at all times. If you already hold a vial, the one number you can check precisely is the arithmetic between the vial and the syringe, which is why this page ends there rather than with a recommendation.
The most repeated dose in this category, 250 mcg a day, is the number that divides a 5 mg vial into exactly 20 injections. It appears in no published study of BPC-157. That is where it came from: the packaging. There is no measured dose to replace it with, and the reason is more specific than "more research is needed". The research every dosing chart descends from was done in rats, and it tested doses a million-fold apart, then reported healing across that whole span 23, so the literature holds no dose-response information to scale up or down from. What follows is the full published record of how much BPC-157 anyone has been given, by which route and in which species, and then the part you can know for certain, which is how to turn a microgram figure into units on a syringe. If you are not yet sure what BPC-157 is supposed to do in the first place, how BPC-157 works covers the mechanism; this page is only about how much.
Why the literature cannot give anyone a dose
A 2003 paper in the Journal of Orthopaedic Research cut the Achilles tendon in rats, then gave BPC-157 once daily by injection into the abdominal cavity, the space around the organs, starting 30 minutes after surgery. The doses were 10 micrograms, 10 nanograms or 10 picograms per kilogram of body weight, a million-fold span from top to bottom. The paper reports full functional and mechanical recovery in the treated groups, measured as load to failure, elastic modulus (Young's modulus), a walking-function score, tissue structure under the microscope and the size of the remaining gap. It does not break those results down dose by dose 2.
A 2010 paper from the same journal repeated that design in rats with a cut knee ligament, running four delivery arms at once. Two were injections into the abdominal cavity, at 10 mcg/kg and 10 ng/kg. The third was a cream at 1.0 microgram of BPC-157 per gram. The fourth was BPC-157 in the drinking water at 0.16 micrograms per millilitre, about 12 millilitres per rat per day, which is roughly 2 micrograms a day in a 300 gram animal rather than any human-scale volume. All four arms are reported as effective on function, mechanical strength, appearance by eye and tissue structure 3. A thousand-fold difference in dose produced one reported answer, and again none of it was in people.
An experiment that gives the same readout at 10 micrograms and at 10 nanograms per kilogram shows that the measurement was not sensitive to dose in that model. That is weaker and less useful than a dose, and it offers no direction to scale in: doubling has no published support and halving has no published support, because the span that produced one answer contains both.
Information regarding the indications, dosing, frequency, and duration of treatment remains unknown.
What doses did the research use?
The whole published record of how much BPC-157 anyone has given, in one table. The third column is the one to read first, because it separates the rat work from the handful of reports involving people.
| Study | Dose and schedule | In people? | Route | What was measured | Source |
|---|---|---|---|---|---|
| 2003, cut Achilles tendon | 10 mcg, 10 ng or 10 pg per kg once daily, first dose 30 minutes after surgery | No, rats | Injection into the abdominal cavity | Load to failure, elastic modulus, a walking-function score, tissue structure, size of the remaining gap | PMID 14554208 2 |
| 2010, cut knee ligament, injected arms | 10 mcg/kg and 10 ng/kg once daily | No, rats | Injection into the abdominal cavity | Function, mechanical strength, appearance by eye, tissue structure | PMID 20225319 3 |
| 2010, cream arm | 1.0 mcg of BPC-157 per gram of cream | No, rats | Applied to the skin | Same measures, reported as effective | PMID 20225319 3 |
| 2010, drinking-water arm | 0.16 mcg/mL, about 12 mL per rat per day, roughly 2 mcg a day in a 300 g animal | No, rats | Swallowed in the drinking water | Same measures, reported as effective | PMID 20225319 3 |
| 2022, pharmacokinetics | Single and repeated doses, three dose levels for the muscle route | No, rats and beagle dogs | Into a vein and into a muscle, no under-the-skin arm | Elimination half-life, absolute bioavailability, excretion, metabolism | PMID 36588717 7 |
| 2025, safety pilot | 10 mg on day one, then 20 mg on day two | Yes, 2 people | One-hour drip into a vein, in 250 cc of saline | Heart, liver, kidney, thyroid and blood-sugar markers; reported side effects. No efficacy measure | PMID 40131143 4 |
| 2021, knee-pain series | Not stated in the paper | Yes, 12 people on BPC-157 alone | Injection into the knee joint | Patient-reported knee pain at a telephone follow-up. No control group, no imaging | PMID 34324435 5 |
| PL-14736, phase 2 in inflammatory bowel disease | Never published | Yes, numbers never published | Never published | Described favourably inside a 2012 review by the group behind the compound, never published as a standalone paper | PMID 22300085 10 |
| NCT07437547, phase 2 trial | Not published | Yes, 120 planned | Injection under the skin, once daily for 14 days | Days to unrestricted sport at 8 weeks; change in MRI injury volume at day 14 | ClinicalTrials.gov 8 |
Two notes on the knee-pain series, because it is the only human musculoskeletal data that exists and it gets cited loosely everywhere. Of the 17 patients in that one-year chart review at a single Florida clinic, 16 were reached by telephone and 12 had received BPC-157 alone; 11 of those 12 reported significant improvement in knee pain, and the paper's own wording is that "this small study suggests" a benefit 5. The 2025 systematic review summarises the same series as 7 of 12 reporting relief lasting beyond six months 1, which is the durability figure rather than the response figure. Both numbers describe the same 12 people, with no control group and no stated dose.
Significant methodological flaws and a lack of controls limit its applicability and reliability.Mayfield CK et al., American Journal of Sports Medicine 2026, on the knee-injection series [[6]]
Where 250 mcg came from
The 250 to 500 mcg figure does not appear in any published study of BPC-157. What it does is divide the vial. BPC-157 is sold in 5 mg and 10 mg vials. Five milligrams is 5,000 micrograms, which is exactly 20 doses of 250 mcg, and ten milligrams is exactly 40. Twenty daily doses is most of a month and forty is most of two.
Nobody knows who wrote the figure down first, and this page will not invent that history. The checkable parts are that it is absent from the literature, that it divides both standard vial sizes without a remainder, and that the one time anyone measured how much a person can be given, the answer landed nowhere near it. Two participants in a 2025 safety pilot received 10 mg on the first day and 20 mg on the second by one-hour drip into a vein, with no measurable change in heart, liver, kidney, thyroid or blood-sugar markers and no side effects reported in those two participants over those two days 4. Two people observed for two days cannot establish that a compound is safe, and the same systematic review that describes the pilot states outright that clinical safety is unknown 1. That exposure is still forty to eighty times the daily figure the charts repeat.
Example placement: the daily figure charts repeat, against the only measured human exposuresmg given to one person in a day
Turning a dose into units on the syringe
One unit note first, because it is the error that matters most: a microgram (mcg) is one thousandth of a milligram (mg), so a 5 mg vial holds 5,000 mcg. This is the part of BPC-157 dosing that is arithmetic and not opinion. A dose is written in micrograms, an insulin syringe is marked in units, where 100 units is one millilitre, and what connects the two is how much water went into the vial. Getting that step wrong produces a clean factor-of-two error, which is larger than any difference the dosing charts argue about.
5 mg vial
| Water added | Concentration | 250 mcg dose | 500 mcg dose | Doses per vial |
|---|---|---|---|---|
| 2 mL | 2,500 mcg/mL | 10 units | 20 units | 20 at 250 mcg |
| 1 mL | 5,000 mcg/mL | 5 units | 10 units | 20 at 250 mcg |
10 mg vial
| Water added | Concentration | 250 mcg dose | 500 mcg dose | Doses per vial |
|---|---|---|---|---|
| 2 mL | 5,000 mcg/mL | 5 units | 10 units | 40 at 250 mcg |
| 3 mL | 3,333 mcg/mL | 7.5 units | 15 units | 40 at 250 mcg |
Why the water volume changes the units but not the doses
Any of those volumes gives the same number of doses, because the water changes only how many units each dose measures. Two millilitres in a 5 mg vial is the arithmetically tidiest, since 250 mcg then falls on the 10-unit mark instead of between marks. The 250 and 500 mcg columns appear in the tables above only because those are the figures readers arrive holding; neither is a dose this page recommends, and the arithmetic is here so that a number someone has already been given is not accidentally doubled. Reconstitution, the word for mixing the dry powder with sterile water, has a general procedure and a bacteriostatic water question of its own, both covered on how to reconstitute peptides; sterile technique and how to read a certificate of analysis sit on the injection hygiene guide. This page owns the BPC-157 numbers only.
How much is in the vial?
Printed on the label, in milligrams
How much water did you add?
Bacteriostatic water, in millilitres
What dose are you taking?
The dose you already intend to use
Which syringe?
Barrel size, printed on the wrapper
Draw to
10 units
on a 0.5 mL insulin syringe (0.1 mL)
- Strength once mixed
- 5 mg/mL
- Doses in the vial
- 20
10 mg in 2 mL makes 5 mg/mL. A 500 mcg dose is 0.1 mL of that, which is 10 units.
This is arithmetic, not advice. It converts a dose you already have into a mark on a syringe. It does not tell you what dose to take. Dosing belongs with a qualified clinician.
Why daily, when it is gone in half an hour
BPC-157 is metabolized in the liver, with a half-life of less than 30 minutes, and is cleared by the kidneys.Vasireddi N et al., HSS Journal 2025, a systematic review of 36 studies [[1]]
The review describes that clearance at the level of organs, while the primary pharmacokinetic work is more specific about the pathway: BPC-157 is cut into small peptide fragments and then into free amino acids, with excretion in urine and bile rather than by the kidneys alone 7. Both descriptions can be true, and the pathway is the part that matters for genetics, which is why liver enzyme genotype still does not apply. What everyone agrees on is the speed. Under half an hour in the blood, while the improvements people report in the uncontrolled knee series were measured months later 5. The usual explanation offered for the daily convention is that a compound cleared that fast cannot be held at a steady blood level, so daily dosing is read as topping up a signal. No published study has compared dosing frequencies for BPC-157, so that reasoning is untested. The monograph sets out what happens after an injection and on what timeline.
Pharmacokinetics, the measurement of how a compound is absorbed and cleared, has been done for BPC-157 once. That study reported elimination half-lives of 15.2 minutes and 5.27 minutes in rats and beagle dogs, every measured value under 30 minutes, with straightforward linear behaviour and no build-up in the blood after seven consecutive days of dosing. It also measured absolute bioavailability for the muscle route at roughly 14 to 19 percent in rats and 45 to 51 percent in beagle dogs 7. Most of an injected dose that did not go straight into a vein never reached the bloodstream intact, and the fraction that did differed about threefold between two species, which is the concrete reason a milligram figure cannot be carried across species.
The one published pharmacokinetic study of BPC-157 tested intravenous and intramuscular injection. It never tested the subcutaneous shot that almost every reader uses, so the most common route is the one nobody has numbers for.
That page owns clearance and the pairing schedule for BPC-157 and TB-500, so this one does not restate either. If you bought both together as the Wolverine stack, our review of that stack covers what the pairing is and is not supported by.
Where do you inject BPC-157?
The most repeated instruction in this category is to inject near the injury, and the published research does not require it. Both rat connective-tissue studies delivered BPC-157 by injection into the abdominal cavity, which is not the belly shot people give themselves: it is a needle into the space around the organs, and nobody does it at home 23. One of the two also reported healing from BPC-157 dissolved in the drinking water 3. A knee ligament improving on a dose that never went near the knee is the opposite of a local-delivery result.
The route you almost certainly use, an injection under the skin (subcutaneous, meaning into the fat layer rather than into a vein or a muscle), is the one with no published measurement behind it: the single pharmacokinetic study had a vein arm and a muscle arm and no under-the-skin arm at all 7. The registered human trial does give its injections under the skin, so a controlled measurement of that route has been registered and is listed as recruiting 8. That entry is sponsor-reported, the sponsor sells peptides, and no results have been posted.
Subcutaneous sites
- AbdomenThe usual first choice. Stay roughly two finger-widths clear of the navel.
- Front or outer thighEasy to reach and easy to see what you are doing.
- Back of the upper armThe fleshy part at the back. Awkward to self-inject.
Can you take BPC-157 orally?
Swallowed BPC-157 has one piece of published support, and it is weaker than it is usually made to sound. The drinking-water arm of the 2010 ligament study reported healing from BPC-157 taken by mouth by rats, at 0.16 mcg/mL and about 12 mL per animal per day, roughly 2 micrograms a day 3. That is a delivery-route result in rats and not a swallowed dose anyone can scale. It is also not a measurement of bioavailability, the fraction of a swallowed dose that reaches the bloodstream intact, and that fraction has never been measured for BPC-157 in a person. The widely repeated instruction to double the dose when swallowing it rests on no published number. What is known about peptide absorption by mouth covers the general problem.
There is one human trial people will bring up here, and it deserves a straight answer. A phase 2 trial in inflammatory bowel disease was run under the name PL-14736 and is described, favourably and briefly, inside a 2012 review by the Zagreb group behind the compound 10. It was never published as a standalone paper, so its route, its dose and its results cannot be checked by anyone outside that work. So the honest position is not that BPC-157 is untested in people. It is that it was tested and you cannot read the test, and an unreadable trial is not a usable dose.
Injection under the skin against swallowing it, on the evidence rather than the marketing
How long did anyone run it for?
Every popular chart prescribes 4 to 8 weeks on with 2 to 4 weeks off. None of those four numbers appears in a published study of BPC-157. The one human schedule registered anywhere is a single injection under the skin daily for 14 days. It is a phase 2 trial in acute grade II hamstring strain confirmed by MRI, 120 participants planned, with a placebo arm and the same standardised rehabilitation programme in both groups, recruiting since 2 February 2026 and sponsored by Hudson Biotech. Neither the participants nor the doctors assessing them know who got the peptide. The registry does not publish the dose. Its primary measures are days to unrestricted sport at 8 weeks and change in MRI injury volume at day 14 8.
How the published research scheduled it
Two weeks is shorter than anything the charts recommend. Whether cycling a peptide on and off has a rationale at all is a separate argument, made on the cycling guide. For BPC-157 specifically, duration has no published answer, which is the position the 2026 orthopaedic primer states in the sentence quoted near the top of this page 6.
Is there a different dose for gut healing, tendonitis or joint pain?
People search for a gut-healing dose and a tendonitis dose, and the evidence does not divide that way. Naming a condition does not change what the published record holds, which is one span of doses in rats that reported one result 23, plus a knee-injection series with no dose stated in the paper 5. The by-condition dosing tables in circulation, including the one this page used to carry, were written rather than measured. What does differ by condition is the context worth reading first: injury recovery, tendonitis, joint pain and gut healing each collect what is known and what is not.
Why two people on the same number report different things
Four ordinary explanations account for most of the variation, and they are ranked here by how much difference they make. Genetics comes after all four, and this page is going to be blunt about why.
- The arithmetic. Two people following the same chart with different water volumes in the vial are not taking the same dose, whatever both of them believe. This is the largest and dullest source of unexplained variation in the category, and the only one a calculator eliminates.
- Consistency. A daily compound taken four days out of seven is a different protocol from the one in the chart, and it is the quietest reason a run produces nothing at all.
- What is in the vial. Purity and fill are unverified on the grey market, and an unknown concentration makes the dose unknown no matter what the syringe reads.
- What is being treated, and how long it has been there. A strain from last week and a tendon problem from five years ago are different jobs, and the age of the problem changes the timescale more than the milligram figure does.
What genetics can and cannot tell you about BPC-157 dosing
No trial has ever sorted BPC-157 responders from non-responders by genotype, in people or in rats. The systematic review that screened 544 articles published between 1993 and 2024 and included 36 of them has no genotype-stratified entry 1, and the 2026 orthopaedic primer does not describe one either 6. Any service quoting you a BPC-157 dose from a saliva sample is quoting a number it made up.
If your protocol stopped working, your liver enzyme genotype is not the reason: peptides are broken down by peptidases, not by the CYP enzymes that clear small-molecule drugs.
The mechanism behind that sentence was measured directly: BPC-157 is cut into fragments and then into free amino acids that join the same pool as any dietary protein, leaving in urine and bile 7. Consumer DNA arrays also cannot reliably resolve CYP3A4 or CYP2D6, so a metabolizer readout for either from an uploaded raw data file would be overreaching even if those enzymes were involved. Our own panel calls 8 pharmacogenes and neither of those two is among them. A PeptidesDNA report scores 39 peptides against a 144-marker panel across 15 pathways, and no line of that output is a dose. CYP status does still matter for the other prescriptions you take, which is a conversation for whoever wrote them.
Is BPC-157 FDA approved, and is it banned in sport?
BPC-157 is not an approved medicine in the United States or anywhere else, and the systematic review quoted above states the lack of FDA approval and the sports ban in its own background section 1. The compounding story gets reported as a green light and is not one. BPC-157 was on the FDA's 503A Category 2 list, the list of substances compounding pharmacies are told not to use. It came off that list in April 2026 because the paperwork behind its nomination was withdrawn, not because the FDA judged it safe, and it has never been moved to the list of bulk substances approved for compounding. An FDA advisory committee then voted on 23 and 24 July 2026 to recommend six peptides for that approved list, BPC-157 among them 9. BPC-157 sits in neither category today, the committee advises and does not bind the FDA, and rulemaking has not begun. Where US law stands in 2026 tracks this properly.
In sport, BPC-157 is prohibited at all times and not in competition only, under the category covering pharmacological substances with no current approval for human therapeutic use 1. There is no permitted amount and no washout window, because the prohibition is outright and not threshold-based. The registered hamstring trial excludes anyone under a formal anti-doping testing programme for exactly that reason 8.
What this page does not cover
- How BPC-157 works for the mechanism, which this page deliberately leaves alone.
- The BPC-157 monograph for evidence tiers, the side-effect groups and the full caution list.
- The brain and nerve route for intranasal use, which is not covered here at all.
- Peptides for beginners for supplies, storage and vendor checks.
The vial is a bigger variable than the number
The largest measurable risk on this page is what is in the bottle. The 2025 systematic review puts it in one line, "Adverse effects are possible due to unregulated manufacturing, contamination, or unknown clinical safety" 1, and the 2026 orthopaedic primer makes the same point about products sold outside any approval pathway 6. An unverified vial makes the dose unverified too, which is why purity sits high in the ranked list above and above the milligram question entirely. Best peptides for healing carries the grey-market sample analysis with its evidence properly labelled, so the numbers are not restated here.
The figure on any chart is convention. Water volume, concentration and units are checkable at your kitchen table in two minutes, and getting them right removes the largest error anyone makes with a BPC-157 vial.
- 250 mcg is vial arithmetic, not a research finding
BPC-157 is sold in 5 mg and 10 mg vials. A 250 mcg dose divides those into exactly 20 and 40 daily injections. The figure appears in no published study of the compound, and it cannot have come from the literature: the two rat studies that carry BPC-157's healing reputation gave doses separated by factors of a thousand and a million, then reported one result across the whole span [[2]][[3]]. The only human exposures anyone has measured are 10 mg and then 20 mg by drip into a vein, in two participants [[4]]. The number came from the packaging.
Sources10
- Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, Voos JE, Apostolakos JM. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS Journal 2025;21(4):485-495. 544 articles screened from 1993 to 2024, 36 included, 35 preclinical and 1 clinical. Source for the half-life quotation, the lack of FDA approval, the all-times sports ban, the absence of clinical safety data, the absence of subcutaneous dosing data and the unregulated-manufacturing line.
- Staresinic M, Sebecic B, Patrlj L, et al. Journal of Orthopaedic Research 2003;21(6):976-983. Transected rat Achilles tendon treated with BPC-157 at 10 mcg, 10 ng or 10 pg per kg once daily by injection into the abdominal cavity, first dose 30 minutes after surgery, with no dose-by-dose breakdown reported. Rats.
- Cerovecki T, Bojanic I, Brcic L, et al. Journal of Orthopaedic Research 2010;28(9):1155-1161. Transected rat knee ligament with four delivery arms: 10 mcg/kg and 10 ng/kg by injection into the abdominal cavity, a 1.0 mcg per gram cream, and 0.16 mcg/mL in the drinking water at about 12 mL per rat per day, all reported effective. Rats.
- Lee E, Burgess K. "Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study." Alternative Therapies in Health and Medicine 2025;31(5):20-24. Two participants, 10 mg on day one and 20 mg on day two by one-hour intravenous infusion in 250 cc of saline, safety endpoints only, no follow-up beyond the acute markers.
- Lee E, Padgett B. "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain." Alternative Therapies in Health and Medicine 2021;27(4):8-13. Retrospective one-year chart review with telephone follow-up: 17 patients, 16 reached, 12 on BPC-157 alone, 11 of those 12 reporting significant improvement. No control group, no imaging, no stated dose.
- Mayfield CK, Bolia IK, Feingold CL, et al. "Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians." American Journal of Sports Medicine 2026;54(1):223-229. Source for both quotations used here: that indications, dosing, frequency and duration of treatment remain unknown, and that the knee-injection series has significant methodological flaws and a lack of controls.
- He L, Feng D, Guo H, et al. "Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157... in rats and dogs." Frontiers in Pharmacology 2022;13:1026182. The only published pharmacokinetic work on BPC-157: intravenous and intramuscular arms only with no subcutaneous arm, elimination half-life under 30 minutes in rats and beagle dogs (15.2 and 5.27 minutes), absolute intramuscular bioavailability of approximately 14 to 19 percent in rats and 45 to 51 percent in beagle dogs, linear kinetics with no accumulation over seven consecutive days, metabolism to small peptide fragments and free amino acids, excretion in urine and bile.
- ClinicalTrials.gov NCT07437547. "A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI." Hudson Biotech. Recruiting, actual start 2 February 2026, 120 participants estimated, quadruple-masked, subcutaneous injection once daily for 14 days, dose not published, no results posted, anyone in a formal anti-doping testing programme excluded. Sponsor-reported record, verified against the v2 API on 27 September 2026.
- US Food and Drug Administration. "July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee." Six peptides recommended for the 503A bulk drug substances list, BPC-157 among them. The page carries no vote tallies. An advisory committee recommendation does not bind the FDA and no rulemaking has followed.
- Sikiric P, Seiwerth S, Rucman R, et al. "Focus on ulcerative colitis: stable gastric pentadecapeptide BPC 157." Current Medicinal Chemistry 2012;19(1):126-132. A review by the group behind the compound, and the only published description of the PL-14736 phase 2 trial in inflammatory bowel disease, which it reports as "so far only tested in clinical phase II" without publishing the dose or the results. The trial itself was never published as a standalone paper.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.
Frequently asked questions
What is the standard BPC-157 dosage?
There is no standard dose in the sense of a measured one. The figure repeated everywhere, 250 to 500 mcg a day by injection under the skin, does not appear in any published BPC-157 study; it is the amount that divides a 5 mg vial into 20 daily doses and a 10 mg vial into 40. The published research was done in rats and used doses spanning a million-fold range, from 10 picograms to 10 micrograms per kilogram of body weight, and reported one healing result across that span [[2]][[3]]. The only measured human exposures are 10 mg and then 20 mg by one-hour infusion into a vein in a two-participant safety pilot [[4]], and the one registered randomized trial does not publish its dose [[8]]. BPC-157 is not an approved medicine, so no clinician can prescribe it as one and its 2026 removal from the FDA's 503A Category 2 list did not make it compoundable. Deferring to a clinician here means deciding whether to use it at all in light of your own history, not obtaining a dose from a chart.
How many units of BPC-157 is 250 mcg?
It depends entirely on how much water went into the vial. A microgram (mcg) is one thousandth of a milligram, so a 5 mg vial holds 5,000 mcg. On a 100-unit-per-mL insulin syringe, the four common combinations are: a 5 mg vial with 2 mL of water gives 2,500 mcg/mL, so 250 mcg is 10 units; 5 mg with 1 mL gives 5,000 mcg/mL, so 250 mcg is 5 units; 10 mg with 2 mL gives 5,000 mcg/mL, so 250 mcg is 5 units; and 10 mg with 3 mL gives 3,333 mcg/mL, so 250 mcg is 7.5 units. The water changes the units per dose and never the number of doses in the vial, which stays at 20 for a 5 mg vial and 40 for a 10 mg vial at that dose size.
How long should a BPC-157 cycle last?
No published study of BPC-157 establishes a cycle length, and the 4 to 8 weeks on with 2 to 4 weeks off that circulates online has no source in the literature. The one human schedule on any registry is a single injection under the skin daily for 14 days, in the phase 2 hamstring-strain trial that began recruiting on 2 February 2026 and whose dose is not published [[8]]. A 2026 American Journal of Sports Medicine primer states that the indications, dosing, frequency and duration of treatment for BPC-157 remain unknown [[6]], which is the fair summary of what exists.
Do CYP enzymes affect BPC-157 dosing?
No. BPC-157 is broken down by peptidases, the enzymes that cut protein chains into fragments and then into ordinary amino acids, and it is not handled by the cytochrome P450 liver enzymes that clear most small-molecule medicines [[7]], so no metabolizer status lengthens or shortens its clearance. CYP status still matters for other medicines you take alongside it, which is a conversation with whoever prescribed them. Consumer DNA arrays also cannot reliably resolve CYP3A4 or CYP2D6, so a metabolizer readout for those two from an uploaded raw data file is not something to rely on.
This article is for informational and educational purposes only. It is not medical advice and does not diagnose, treat, cure, or prevent any disease. Consult a qualified healthcare professional before starting any peptide protocol. Individual results vary. Some outbound links are affiliate links, at no extra cost to you.